Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Correlations of recurrence after radical surgery for esophageal cancer with glucose-lipid metabolism, insulin resistance, inflammation, stress and serum p53 expression.
|
31646823 |
2020 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Esophageal cancer (ESC) is one of the most deadly diseases for human. p53 in most cancers, including ESC cell, is mutated, and the mutated p53 losses its original function and acquires "gain of function" that allows for promoting the hallmarks of cancer, such as antiapoptosis, metastasis, invasion, angiogenesis, and resistance to chemotherapy.
|
31354907 |
2019 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Among the down-regulated miRNAs in SCI, 21, 19 and 20 miRNAs were potentially associated with hematological, bladder and esophageal cancer, respectively, and three target genes (<i>TP53, CCND1 and KRAS</i>) were common to all three types of cancer.
|
31444279 |
2019 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Data on the combined effect of p53 protein accumulation and <i>TP53</i> genomic deactivation in large scale studies for esophageal cancer are currently lacking.
|
30881503 |
2019 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
In summary, shikonin can sensitize esophageal cancer cells to paclitaxel-treatment by promoting cell mitotic arrest and reinforcing the susceptibility of esophageal cancer cells to apoptosis induced by paclitaxel, which is potentially associated with altered levels of Bcl-2 and p53.
|
31452796 |
2019 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Zerumbone can inhibit the proliferation and induce apoptosis of esophageal cancer EC-109 cells, and its induction of apoptosis may be realized through upregulating the mRNA expression of P53 and downregulating the mRNA expression of Bcl-2, and upregulating the protein expression of P53 and downregulating the protein expression of Bcl-2.
|
30197671 |
2018 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Frequent aberrant p53 and Fhit expression in endoscopically resected superficial hypopharyngeal cancer and esophageal cancer.
|
28693209 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The sensitivity of the p53 fluorescent in situ hybridization probe was13.3 % for any abnormality, 10 % for intestinal metaplasia, and 0 % for dysplasia or esophageal cancer.
|
27561634 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Methylation and expression of RECK, P53 and RUNX genes in patients with esophageal cancer.
|
29113164 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We searched PubMed, Ovid MEDLINE, Embase, and Current Contents Connect to identify studies published between January 1990 and February 2016 of esophageal cancer populations that measured p53 expression and/or mutation status and reported hazard ratios (HRs), or adequate data for estimation of HRs for survival for p53-defined subgroups.
|
27882726 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
The frequencies of non-synonymous single nucleotide variants (SNVs) in the TP53 family members TP63 and TP73 were relatively low, although genes with increased frequencies of SNVs were as follows: PTEN (11.7%) in breast cancer, CDKN2A (11.1 and 9.6%) in pancreas and head and neck cancers, and ATM (18.0 and 11.1%) in liver and esophageal cancers.
|
28258440 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
However, p53 variant/polymorphism was not statistically associated with esophageal cancer risk under the heterozygous model (Pro/Pro vs Arg/Pro).
|
28459370 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Meta-analysis of P53 for predicting esophageal cancer response has been reported before and is not included in our study.
|
29113666 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
<b>MATERIALS AND METHODS:</b> The prevalence of HPV in individuals with and without esophageal cancer (EC) was determined by using multiplex PCR; p16 and p53 protein levels were assessed by immunohistochemistry (IHC).
|
28529620 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
HPV infection and p53 and p16 expression in esophageal cancer: are they prognostic factors?
|
29046713 |
2017 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We also observed a significant increase in ERCC1 expression, and decrease in p53 and EGFR expression, in EC-9706 cells treated with SNX-2112 (P < 0.05), indicating the regulation of EC by SNX-2112.
|
27420968 |
2016 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
Combination therapy of carbon-ion beam with the far upstream element-binding protein (FBP)-interacting repressor, FIR, which interferes with DNA damage repair proteins, was proposed as an approach for esophageal cancer treatment with low side effects regardless of TP53 status.
|
26241176 |
2016 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
The crucial molecular targets such as p53 may provide great clinical value in treatment, as well to provide new ideas for esophageal cancer therapy.
|
26498375 |
2015 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
CTD_human |
Genomic landscape of cutaneous T cell lymphoma.
|
26192916 |
2015 |
Malignant neoplasm of esophagus
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To clarify the effects of p53 codon 72 polymorphism on the risk of EC, we performed a meta-analysis on the Chinese population.
|
26345834 |
2015 |
Malignant neoplasm of esophagus
|
0.700 |
Biomarker
|
disease |
BEFREE |
To test the value of TP53 as a biomarker prognosing outcome in patients with neoadjuvantly treated esophageal cancer.
|
25135238 |
2014 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Expression of bcl-2 and p53 in induction of esophageal cancer cell apoptosis by ECRG2 in combination with cisplatin.
|
24606472 |
2014 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
PLCE1 suppresses p53 expression in esophageal cancer cells.
|
24766303 |
2014 |
Malignant neoplasm of esophagus
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
TP53 Pro72 allele is enriched in oral tongue cancer and frequently mutated in esophageal cancer in India.
|
25436609 |
2014 |
Malignant neoplasm of esophagus
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
p63 is a member of the p53 protein family and plays a crucial role in epithelial development. p63 is expressed in many types of tumors including esophageal cancer; however, its function in cancer is controversial and its role in esophageal cancer has not been clearly established.
|
24718831 |
2014 |